Hormone Therapy Facts for Vasomotor Symptoms & Cardiometabolic Risk

Find out how hormone therapy can help manage vasomotor symptoms, cardiometabolic risk, and improve quality of life.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through an easy-to-follow journey through menopause, with a special focus on vasomotor symptoms (VMS), such as hot flashes and night sweats. I explain the physiological underpinnings of the menopausal transition, outline the STRAW +10 staging framework, and discuss the latest research on the hypothalamic KNDy neuron network, which underlies many vasomotor disturbances. I present modern, evidence-based strategies including lifestyle, mind-body therapies, non-hormonal medications, and hormone therapy — with clear reasoning for why we choose transdermal estrogen when possible and how progesterone safeguards the endometrium.
I also introduce our multidisciplinary care model at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, where I work in close collaboration with Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933). Dr. Cardenas serves as our Medical Director and Collaborative Physician, providing medical oversight that complements my integrative chiropractic and functional medicine approach. Together, we integrate chiropractic care, internal medicine, rehabilitation, personal injury care, and functional medicine to deliver a comprehensive plan for women navigating menopause. Throughout, I include clinical observations drawn from my published insights and professional profile.

Understanding Menopause: Definitions, Timelines, and Systemic Impact

Menopause is a natural, systemic transition characterized by declining ovarian follicular function, culminating in the final menstrual period (FMP) and confirmed after 12 consecutive months without menstruation. This transition is governed by age-related changes in the hypothalamic-pituitary-ovarian (HPO) axis and affects multiple organ systems.
Key points:

• The median age of menopause in the United States is about 52.5 years.
• Early menopause occurs before 45, and premature menopause occurs before 40, prompting further medical evaluation.
• Menopause exerts systemic effects on the skeletal, cardiovascular, genitourinary, and nervous systems, among others.

Why this matters: When estrogen and progesterone decline, it is not just reproductive tissues that change; vascular tone, bone remodeling, thermoregulation, neurotransmission, and metabolic pathways are all influenced by this hormonal shift. Recognizing menopause as a multi-system process keeps our care holistic and coordinated.

The STRAW +10 Staging System: A Clinical Roadmap

The STRAW +10 criteria standardize the stages of reproductive aging and help clinicians and patients contextualize symptoms and lab findings:

• Stage -5 to -3 (Reproductive years): Regular cycles; FSH in normal range.
• Stage -2 (Menopausal transition/perimenopause):
  • Menstrual cycles become variable; length can change by 7 days or more.
  • Later in transition, amenorrhea may occur for 60+ days.
  • FSH begins to rise (late transition often shows FSH > 25 IU/L).
  • VMS frequently starts here.
• Stage +1 to +2 (Postmenopause):
  • Menstruation ceases, and FSH remains elevated.
  • VMS often peaks in early postmenopause (+1) and may persist into late postmenopause (+2).

Why staging helps: Symptom patterns — especially hot flashes — often intensify around the FMP and early postmenopause. Understanding where you are in the STRAW +10 framework helps tailor testing, treatment timing, and expectations.

The Hormonal Symphony: Inhibin, FSH, Estrogens, Progesterone, and Androgens

The menopausal transition reflects a coordinated shift among several hormonal actors:

• Inhibin B: Declines early. Reduced inhibitory feedback to the pituitary leads to rising FSH.
• FSH (Follicle-Stimulating Hormone): Rises and fluctuates as the pituitary attempts to stimulate waning ovarian function.
• Progesterone: Falls with decreasing ovulation frequency, contributing to cycle irregularity and sleep/mood changes.
• Estrogens:
  • Estradiol (E2): The most potent premenopausal estrogen; declines markedly after menopause.
  • Estrone (E1): Becomes predominant postmenopause, produced in adipose tissue and adrenal pathways; decline is less pronounced than estradiol.
• Testosterone: Gradually declines with age; typically remains within lower-normal ranges in post-menopausal women.
• DHEAS: Declines with age but is relatively independent of menopause per se.

Why routine testing is limited: For women over 45, hormone levels fluctuate daily, reducing the clinical utility of single-point testing. Diagnosis remains primarily clinical (history and cycles), though testing can be pursued through shared decision-making when desired, with results interpreted cautiously.

The Broad Symptom Spectrum: VMS, GSM, Cognitive, Metabolic, and Musculoskeletal Changes

Menopause can present across multiple domains:

• Vasomotor Symptoms (VMS): Hot flashes and night sweats.
• Genitourinary Syndrome of Menopause (GSM): Vaginal dryness, dyspareunia, urinary urgency, and stress incontinence.
• Psychological and Cognitive: Mood swings, anxiety, depression, sleep disturbance, brain fog, and memory changes.
• Metabolic/Cardiovascular: Central weight gain, dyslipidemia, and elevated CVD risk.
• Musculoskeletal/Dermatological: Arthralgia, decreased bone density, dry skin, brittle nails, thinning hair, and changes in breast fullness.

Clinical observation: Many patients, like “Miss Jenny” — a composite representation of common clinical scenarios — initially present with severe night sweats and only later recognize associated joint pain, mood changes, and urinary symptoms. Bringing these into one coherent picture is often the first empowering step in care.

Why Hot Flashes Occur: Thermoneutral Zone and KNDy Neuron Physiology

A hot flash is a sudden, intense sensation of heat accompanied by flushing and sweating, often followed by chills. Over 80% of women experience VMS before or after the FMP, sometimes lasting an average of 7 years, with notable variability across populations.
Physiology of VMS:

• The hypothalamus maintains a thermoneutral zone — a range where the body does not need active cooling or warming.
• Estrogen helps keep this zone wide and stable.
• With estrogen decline, the thermoneutral zone narrows. Minor increases in core temperature can trigger peripheral vasodilation and diaphoresis — the hallmark hot flash.
• KNDy neurons (kisspeptin/neurokinin B/dynorphin) in the hypothalamus are central players. Neurokinin B stimulates these neurons; estrogen normally inhibits them. When estrogen falls, unopposed NKB leads to overactive KNDy signaling and hot flashes (Rance, 2017).

Clinical implications:

• Targeting NK3 receptors offers a non-hormonal path to VMS relief, especially for patients who cannot use estrogen.
• Severe, prolonged VMS correlates with increased cardiovascular risk, warranting proactive assessment and management (Thurston et al., 2021).

References:

• Rance, K. N. (2017)
• Thurston, R. C. et al. (2021)

---

Aligned & Empowered: Chiropractic Conversations on Women’s Health- Video

---

Our Multidisciplinary Care Model: Internal Medicine Oversight and Integrative Chiropractic

I practice at Injury Medical Clinic PA — also known as Mission Plaza Injury Medical Clinic — in El Paso, Texas, within a multidisciplinary, integrative model that is common to advanced integrative and injury care clinics.

• I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, a dual-licensed Doctor of Chiropractic and Family Nurse Practitioner with extensive training in functional medicine. My clinical observations and practice insights are available at my professional sites:
  • Clinical observations in integrative chiropractic and functional medicine
  • Professional profile and clinical insights
• Our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749; Texas MD License #J2933), is Board Certified in Internal Medicine and brings over 40 years of clinical experience. Her medical oversight ensures diagnostic precision, safe medication management, and robust integration with internal medicine best practices.

How this integration works:

• Medical oversight (Dr. Cardenas): Guides diagnostics, manages comorbidities, supervises hormone therapy (HT) and non-hormonal prescriptions, and ensures evidence-based protocols.
• Integrative chiropractic and functional medicine (Dr. Jimenez): Addresses neurological regulation, musculoskeletal integrity, stress physiology, nutrition, and biochemical imbalances that influence symptom burden.
• Rehabilitation and personal injury care: Provides targeted therapy for pain, mobility, and functional restoration — particularly valuable when arthralgia, postural changes, or fall risk emerge during menopause.

This blended care model creates a seamless, patient-centered pathway in which a coordinated team manages complex menopausal presentations under one roof.

Treatment Spectrum: Lifestyle, Mind-Body, Non-Hormonal, and Hormonal Therapies

Menopause is deeply personal; decisions are guided by shared decision-making, clinical history, and patient preference. We build a plan from the least invasive to the most advanced, ensuring safety, efficacy, and alignment with patient goals.
Lifestyle and home management:

• Dress in layers; maintain a cool sleep environment.
• Identify triggers: caffeine, alcohol, spicy foods.
• Hydration and regular exercise (aerobic plus resistance) to support vascular health and mood regulation.

Mind-body therapies:

• Cognitive Behavioral Therapy (CBT) can reduce the severity (though not always the frequency) of hot flashes and improve sleep and coping skills.
• Clinical hypnosis may offer non-pharmacologic symptom relief; scalability can be limited by access and cost.

Non-hormonal medications:

• SSRIs/SNRIs (e.g., paroxetine) can reduce VMS frequency/intensity for patients avoiding hormones.
• NK3 receptor antagonists directly target KNDy neuron pathways, offering modern, mechanism-based VMS relief.

Why these work:

• CBT/hypnosis recalibrate cognitive appraisals and autonomic arousal, blunting thermoregulatory triggers.
• SSRIs/SNRIs modulate serotonergic pathways that influence hypothalamic thermoregulation.
• NK3RAs precisely address the NKB-KNDy axis, treating VMS at its neuronal source.

Hormone Therapy: Indications, Formulations, and the Case for Transdermal Estrogen

When symptoms are moderate to severe, hormone therapy (HT) is often the most effective strategy. The FDA-approved indications include:

• Moderate to severe VMS
• Prevention of bone loss
• GSM symptoms (prefer local vaginal estrogen when GSM is the sole complaint)
• Premature or early estrogen deficiency (before age 40)

Why transdermal is often preferred:

• First-pass hepatic metabolism is avoided. Oral estrogen increases hepatic production of clotting factors, elevating DVT/PE risk; transdermal routes minimize this risk.
• Stable serum levels reduce peaks/troughs, improving tolerability and symptom control.
• Lower effective doses achieve clinical benefit without unnecessary hepatic load.

Common transdermal options:

• Estradiol patches (weekly or biweekly; e.g., generics, Vivelle-Dot, Climara)
• Estradiol gels/mists (e.g., Divigel, Evamist) — remind patients to let applications dry completely before dressing

Oral therapies:

• Estrogen-only for women with hysterectomy (e.g., conjugated equine estrogens, plant-derived estradiol). Shared decision-making respects ethical or preference concerns about animal-derived products.
• Combination estrogen + progestin for women with a uterus:
  • Prevents endometrial hyperplasia/cancer by opposing estrogen-induced endometrial proliferation.
  • Micronized progesterone (Prometrium) is often preferred for tolerability and possibly lower breast cancer risk compared to certain synthetic progestins.

Special formulations:

• CEE + SERM (bazedoxifene): A combination that protects the uterus (SERM acts as an antagonist there), supports bone health, and addresses VMS without a traditional progestin.
• Parenteral estradiol (IM estradiol valerate/cypionate): In select, severe cases, provides sustained levels; pharmacokinetics differ (valerate peaks faster; cypionate is smoother).

Clinical guardrails:

• Initiate HT ideally within 10 years of menopause onset and before age 60 to align with the timing hypothesis favoring cardiovascular safety.
• For migraines with aura, prefer low-dose transdermal to reduce serum fluctuations that can trigger events.
• In VTE history or hyperlipidemia, transdermal is safer. Coordinate care with internal medicine or specialist oversight.

References:

• ACOG Practice Bulletin No. 141 (2014)
• The NAMS 2022 Position Statement Advisory Panel (2022)
• Rossouw et al., WHI (2002)
• Vinogradova et al. (2019)
• Manson et al. (2013)
• Collaborative Group on Hormonal Factors in Breast Cancer (2019)
• Fournier et al. (2008)

Expected Side Effects, Adverse Risks, and Monitoring Protocols

First 3–6 months: set expectations

• Irregular bleeding/spotting (common early; ensure progesterone compliance)
• Breast soreness, bloating, headaches
• Stomach cramps, transient hair changes

Long-term risks to discuss transparently:

• Stroke: Risk increases with both estrogen-only and combination therapy; lower risk with transdermal versus oral.
• DVT/PE: Elevated with oral conjugated estrogens; reduced with transdermal.
• Endometrial cancer: Prevented by daily micronized progesterone in women with a uterus; local vaginal estrogen has minimal systemic exposure.
• Breast cancer: Risk increases with duration — typically after 3–5 years for combined therapy and ~7 years for estrogen-only; risk profile may be more favorable with micronized progesterone than with synthetic progestins.
• Gallbladder disease: Slightly increased risk.

Annual monitoring (medical oversight is essential):

• Review tolerability, efficacy, and side effects; consider dose reduction if stable and symptom-free.
• Pelvic exam and clinical breast exam.
• Cervical cancer screening per guidelines; ensure mammograms are up to date.
• Screen for osteopenia/osteoporosis (DEXA as appropriate).
• Assess cardiometabolic health: BP, lipids, A1c/glucose, cardiovascular symptoms.
• Address new comorbidities; coordinate specialist care when indicated.

Internal medicine supervision:

• Dr. Cardenas ensures HT decisions are made within a comprehensive medical context and that surveillance aligns with best practices in women’s health.

Genitourinary Syndrome of Menopause: Local Estrogen Strategies that Work

GSM symptoms often persist despite systemic therapy. In these cases:

• Use local vaginal estrogen (cream, ring, tablet) to restore epithelial thickness, lubrication, and pH balance.
• Apply a small, pea-sized amount internally and carefully over the urethral meatus to target the periurethral estrogen receptors. Clinically, this reduces overactive bladder symptoms and recurrent UTIs, improving quality of life.

Why local therapy excels:

• Direct tissue exposure with minimal systemic absorption.
• Supports urogenital mucosa and local immune defense, reducing dysbiosis and infection propensity.

Cardiometabolic and Cognitive Considerations: The Timing Hypothesis and Beyond

Evidence supports the timing hypothesis:

• Initiating HT before age 60 or within 10 years of menopause improves endothelial function, lipid profiles, and inflammatory markers, reducing CVD risk.
• Type 2 diabetes risk appears lower with HT, likely via improved insulin sensitivity and glucose metabolism (NAMS, 2022; Boardman et al., 2015).

Neurocognitive benefits:

• Estrogen’s neuroprotective effects may improve mood stability, sleep architecture, and cognitive clarity, especially during the transition when fluctuations are most disruptive.

References:

• The NAMS 2022 Position Statement Advisory Panel (2022)
• Boardman et al. (2015)
• Mishra et al. (2021)

Integrative Chiropractic Care: Nervous System Regulation, Musculoskeletal Health, and Functional Medicine

My integrative chiropractic approach complements medical management by targeting the neurological, structural, and metabolic dimensions of menopause:
Nervous system regulation:

• Chiropractic adjustments and neuromuscular re-education reduce nociceptive input, improve autonomic balance, and support hypothalamic regulation. When stress-related signals abate, VMS triggers often lessen, and sleep improves.
• By optimizing spinal biomechanics, we reduce physical stressors that amplify HPA-axis dysregulation and cortisol volatility.

Musculoskeletal health:

• Menopause-related arthralgia and stiffness reflect changes in cartilage lubrication, connective tissue elasticity, and inflammatory tone under low-estrogen states.
• We implement joint-specific adjustments, soft tissue therapies, and corrective exercise programs.
• Weight-bearing and strength training support bone density and fracture prevention; balance training mitigates the risk of falls.

Functional medicine and nutrition:

• Personalized plans assess micronutrient status (e.g., Vitamin D, calcium, magnesium, Vitamin K2) and inflammation markers to support bone and vascular health.
• Anti-inflammatory nutrition and phytoestrogen-rich foods may modestly ease symptoms and reduce cardiometabolic risk.
• Stress modulation (mindfulness, breath training) lowers sympathetic overdrive, a VMS trigger.
• Targeted supplementation (e.g., magnesium for sleep/mood, B vitamins for energy/nerve function, and adaptogens) is selected on a case-by-case basis, grounded in evidence and monitored for efficacy (Geller & Studee, 2005).

How we integrate:

• Under Dr. Cardenas’s medical direction, we align HT or non-hormonal medications with chiropractic and functional strategies, monitoring outcomes and making collaborative adjustments for safety and maximal relief.

References:

• Geller & Studee (2005)
• Jimenez (2025a, 2025b)

Shared Decision-Making and Follow-Up: Ethical, Personalized Care

Every treatment plan rests on an honest, individualized conversation:

• We present a balanced, evidence-based picture of benefits and risks.
• We respect patient preferences, cultural perspectives, and prior experiences.
• We clarify the importance of progesterone in women with a uterus.
• We outline expected early side effects versus warning signs to call the clinic.
• We revisit the plan as symptoms or comorbidities evolve, avoiding automatic discontinuation at age 60 and opting for reassessment instead.

Clinical example:

• “Miss Jenny,” exhausted by nightly sweats and daytime fatigue, began transdermal estradiol with micronized progesterone after shared decision-making. At six weeks, she reported sleeping through the night with VMS resolution and improved mood. This kind of transformation is common when therapy is timed well and paired with integrative support.

Practical Takeaways: Building Your Personalized Plan

• Start with lifestyle: cool room, trigger management, exercise.
• Consider CBT/hypnosis for severity reduction and coping.
• Explore non-hormonal pharmacology if estrogen is contraindicated or undesired.
• If using HT, prefer transdermal estrogen where appropriate; ensure progesterone protection with a uterus.
• Address GSM with local estrogen; include periurethral application to reduce OAB/UTI.
• Integrate chiropractic, rehabilitation, and functional medicine for nervous system regulation, pain reduction, bone health, and metabolic support.
• Monitor annually under internal medicine oversight; adjust dosing and strategies based on outcomes and evolving health.

References

• ACOG Practice Bulletin No. 141: Management of menopausal symptoms (American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology, 2014).
• The 2022 hormone therapy position statement of The North American Menopause Society (The NAMS 2022 Hormone Therapy Position Statement Advisory Panel, 2022).
• Risks and benefits of estrogen plus progestin in healthy post-menopausal women: Principal results from the Women’s Health Initiative randomized controlled trial (Rossouw et al., 2002).
• Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials (Manson et al., 2013).
• Use of hormone replacement therapy and risk of venous thromboembolism: Nested case-control studies using the QResearch and CPRD databases (Vinogradova et al., 2019).
• Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence (Collaborative Group on Hormonal Factors in Breast Cancer, 2019).
• Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study (Fournier et al., 2008).
• Hormone therapy for preventing cardiovascular disease in post-menopausal women (Boardman et al., 2015).
• The menopause transition: Signs, symptoms, and management options (Santoro et al., 2021).
• Vasomotor symptoms and cardiovascular disease risk in women: A narrative review (Thurston et al., 2021).
• The KNDy neuron and its role in the hot flushes (Rance, 2017).
• Botanical and dietary supplements for menopausal symptoms: What works, what doesn’t (Geller & Studee, 2005).
• Duration of estrogen exposure during reproductive years, age at menarche and age at menopause, and risk of cardiovascular disease events, all-cause and cardiovascular mortality: A systematic review and meta-analysis (Mishra et al., 2021).
• Clinical observations in integrative chiropractic and functional medicine (Jimenez, 2025a).
• Professional profile and clinical insights (Jimenez, 2025b).

SEO tags: menopause, vasomotor symptoms, hot flashes, night sweats, KNDy neurons, transdermal estrogen, micronized progesterone, genitourinary syndrome of menopause, cognitive behavioral therapy, NK3 receptor antagonists, North American Menopause Society, ACOG guidelines, cardiovascular timing hypothesis, osteoporosis prevention, chiropractic care, functional medicine, integrative women’s health, El Paso Texas, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Alex Jimenez DC APRN, Dr. Maria Guadalupe Cardenas MD